AC Immune (ACIU) Net Equity Issued and Repurchased (2015 - 2025)

AC Immune (ACIU) has 11 years of Net Equity Issued and Repurchased data on file, last reported at -$1251.2 in Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$1251.2 in Q4 2025; TTM through Dec 2025 was $7893.4, a 0.31% change from a year earlier, with the FY2025 full-year figure at $7236.8, down 9.43% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at -$1251.2, down from $6250.5 in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for ACIU reached as high as $4.7 million in Q4 2021 and fell as low as -$13272.7 in Q1 2021.
• Historically, Net Equity Issued and Repurchased has averaged $282575.1 across 5 years, with a median of $3357.3 in 2024.
• Across the five-year window, Net Equity Issued and Repurchased jumped 8881.88% in 2021 and tumbled 699.09% in 2023, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $4.7 million in 2021, then tumbled by 99.98% to $1035.5 in 2022, then surged by 444.38% to $5636.8 in 2023, then sank by 79.52% to $1154.2 in 2024, then slumped by 208.4% to -$1251.2 in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were -$1251.2 in Q4 2025, $6250.5 in Q3 2025, and $8455.2 in Q2 2025.